JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lefrançois-Martinez, A.-M.
Right arrow Articles by Jean, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lefrançois-Martinez, A.-M.
Right arrow Articles by Jean, C.

J Biol Chem, Vol. 274, Issue 46, 32875-32880, November 12, 1999


Product of Side-chain Cleavage of Cholesterol, Isocaproaldehyde, Is an Endogenous Specific Substrate of Mouse Vas Deferens Protein, an Aldose Reductase-like Protein in Adrenocortical Cells*

Anne-Marie Lefrançois-MartinezDagger §, Colette TournaireDagger , Antoine MartinezDagger , Michel BergerDagger , Sylviane DaoudalDagger , Denis Tritsch, Georges VeyssièreDagger , and Claude JeanDagger

From Dagger  UMR CNRS 6547, Université Blaise Pascal, Les Cézeaux, 63177 Aubière, Cedex, France and  URA31 CNRS, Université Louis Pasteur, 67000 Strasbourg, France

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Mouse vas deferens protein (MVDP) is an aldose reductase-like protein that is highly expressed in the vas deferens and adrenal glands and whose physiological functions were unknown. We hereby describe the enzymatic characteristics of MVDP and its role in murine adrenocortical Y1 cells. The murine aldose reductase (AR) and MVDP cDNAs were expressed in bacteria to obtain recombinant proteins and to compare their enzymatic activities. Recombinant MVDP was functional and displayed kinetic properties distinct from those of murine AR toward various substrates, a preference for NADH, and insensitivity to AR inhibitors. For MVDP, isocaproaldehyde, a product of side-chain cleavage of cholesterol generated during steroidogenesis, is the best natural substrate identified so far. In Y1 cells, we found that NADH-linked isocaproaldehyde reductase (ICR) activity was much higher than NADPH-linked ICR activity and was not abolished by AR inhibitors. We demonstrate that in Y1 cells, forskolin-induced MVDP expression enhanced NADH-linked ICR activity by 5-6-fold, whereas no variation in ICR-linked NADPH activity was observed in the same experiment. In cells stably transfected with MVDP antisense cDNA, NADH-linked ICR activity was abolished even in the presence of forskolin, and the isocaproaldehyde toxicity was increased compared with that of intact Y1 cells, as measured by isocaproaldehyde LD50. In Y1 cells transfected with MVDP antisense cDNA, forskolin-induced toxicity was abolished by aminoglutethimide. These results indicate that in adrenocortical cells, MVDP is responsible for detoxifying isocaproaldehyde generated by steroidogenesis.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Aldoketoreductases (AKRs)1 are monomeric oxidoreductases that catalyze the NADPH-dependent conversion of aldehydes and ketones to their corresponding alcohols (1). Among the AKR superfamily, aldose reductase (AR) has been a focus of interest because of its potential role in the development of secondary diabetic complications (2). In agreement with its broad substrate specificity, AR is thought to accomplish varying physiological roles in osmotic homeostasis (3), steroid conversion (4), and detoxification against xenobiotic and endogenous aldehydes (5). To date, the AKR superfamily consists of at least 42 members that differ in their primary structure, substrate specificities, and catalytic properties.

Adult mouse vas deferens contains a large amount of a major protein (mouse vas deferens protein (MVDP)) with an apparent molecular mass of 34,500 Da (6). Recently, it has been shown that MVDP expression is not restricted to the vas deferens, and high levels of MVDP mRNA were found in the adrenal glands (7). Androgens have been shown to be the primary regulating factors of MVDP expression in the vas deferens (8); and recent studies suggest that cAMP is a key regulator of adrenal MVDP expression (9). MVDP shares ~70% amino acid identity with human, rabbit, rat, and mouse ARs (10, 11), and MVDP gene structure is similar to that of the human AR gene (12). However, MVDP is more closely related to the mouse fibroblast growth factor-regulated protein FR-1 (13), Chinese hamster ovary reductase (14), the human AR-like gene ALR1 (15), and human small intestine reductase (16). These proteins share ~80-90% sequence identities and form a distinct subgroup within the AKR1B group according to the new nomenclature proposed by Jez et al. (17). The enzymatic nature of MVDP (AKR1B7 in agreement with the proposed nomenclature (17)) has not yet been demonstrated.

In this study, we have compared the enzymatic characteristics and substrate specificity of MVDP with those of mAR, and we have focused on its physiological role in adrenal glands. The data indicate that MVDP acts as a major reductase for isocaproaldehyde formed during steroidogenesis.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Chemicals-- Tolrestat was a gift from Wyet-Ayerst, Sorbinil from Pfizer, and Imirestat from Alcon Laboratories. Isocaproaldehyde was prepared according to the method of Matsuura et al. (18). 4-Hydroxynonenal was provided by Interchim. All other chemicals were purchased from Sigma.

Recombinant Protein Production-- MVDP and mAR cDNAs were obtained by polymerase chain reaction amplification with MVDP pUC13 (10) and mAR pGEMT (pmAR13) (11) as templates, respectively, and with outside primers containing engineered 5'- BamHI and 3'-EcoRI sites (5'-BamHI primer, 5'-GCAGGATCCATGGCCACCTTCGTGGAACTC-3'; and 3'-EcoRI primer, 5'-ATTGAATTCTCAGTGTTACCATACTACATGC-3'). Recombinant MVDP and mAR were expressed in Escherichia coli by inserting their respective cDNAs into the BamHI and EcoRI sites of pET28a (Novagen) to produce N-terminal fusions with six histidine residues. Recombinant MVDP and mAR were produced in BL21(DE3) pLysS cells upon isopropyl-beta -D-thiogalactopyranoside induction and purified by nickel affinity chromatography according to the manufacturer's instructions (Novagen). For each protein, column fractions were analyzed by SDS-PAGE, and those containing the purified protein were pooled and stored at 4 °C.

Y1 Cell Lines Expressing MVDP Antisense RNA by Stable Transfection-- The pCR3 vector (Invitrogen) harboring the neomycin resistance gene was used to express MVDP antisense RNA in murine adrenocortical Y1 cells (19) in stable transfection experiments. The complete MVDP cDNA was obtained by XbaI/EcoRI digestion of pET-MVDP and inserted in antisense orientation in pCR3. This construct was named pCR3-AS. Y1 cells were transfected with either 5 µg of pCR3-AS or pCR3-EV (empty control plasmid) vector by lipofection using N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium salts (Roche Molecular Biochemicals). After a 48-h recovery period, 400 µg/ml G418 was added to the medium. G418-resistant cells were selected, isolated by limiting dilution, and then propagated. Cellular clones harboring either the pCR3-AS or pCR3-EV vector were named AS and EV cells, respectively. The presence of the pCR-AS vector (6.3 kilobases) in the neomycin-resistant selected Y1 cells was identified by Southern blot analysis after EcoRI digestion of cellular genomic DNA. The Southern blot was hybridized with a MVDP probe (1226-base pair XbaI/EcoRI fragment covering the complete MVDP cDNA) labeled by random priming.

Cell and Tissue Extracts-- Y1 cells were routinely cultured as described previously in Dulbecco's modified Eagle's medium/nutrient mixture F-12 supplemented with 10% fetal calf serum (9). AS or EV stably transfected Y1 cellular clones were routinely cultured in the same medium containing 200 µg/ml G418. 24 h prior to treatment with various hormones or drugs, G418 was removed. Human H295R adrenocortical cells were cultured as described previously (9). 24 h before harvest, cells were cultured under basal conditions or in the presence of 10-5 M forskolin or 75 mM NaCl. Adrenal glands were removed from adult male CD1 mice. Tissues or cells were immediately homogenized in 0.1 M sodium phosphate buffer (pH 6.6) containing 1 mM dithiothreitol. The homogenates were centrifuged at 105,000 × g for 1 h, and the supernatants were collected and immediately used for enzymatic assay or subsequent SDS-PAGE analysis.

Enzymatic Assay-- The standard reaction mixture for the reductase activities contained 0.1 M sodium phosphate buffer (pH 6.6), 0.4 M ammonium sulfate, and appropriate amounts of NAD(P)H, substrate, and enzyme or protein extracts as indicated for each experiment. The reaction was carried out at 25 °C, and the decrease in NAD(P)H was monitored by spectrophotometer at 340 nm. Reactions were routinely started by the addition of enzyme or protein extracts. Controls without substrate or without enzyme were run simultaneously. One enzyme unit is defined as the change at 340 nm corresponding to the oxidation of 1 µmol of NAD(P)H.

Northern Blot Analysis-- Northern bolt analysis of total RNAs isolated from Y1 cells was performed according to the method previously described (9).

Western Blot Analysis-- Frozen cell or tissue samples were homogenized in 250 mM Tris-HCl (pH 7.5) and 0.4 mM phenylmethylsulfonyl fluoride. Soluble tissue or cell extracts (20 µg of proteins) or recombinant MVDP or AR was subjected to SDS-PAGE or NEpHGE and transferred to nitrocellulose membranes. Blots were treated as previously described (9) and then incubated with either primary anti-MVDP monoclonal antibody (ascites B263) at a 1:700 dilution or rabbit anti-rat AR serum at a 1:3000 dilution for 1 h at room temperature. When NEpHGE was performed, blots were treated with primary rabbit anti-MVDP serum at 1:5000 dilution. Peroxidase-conjugated anti-mouse or anti-rabbit secondary antibodies were added at a 1:15,000 dilution for 1 h at room temperature. Peroxidase activity was detected with the enhanced chemiluminescence system (ECL, Amersham Pharmacia Biotech).

Forskolin and Isocaproaldehyde Toxicity Measurement-- Stably transfected Y1 cellular clones (AS19 or EV4 cells) were plated in 1 ml of fresh medium in 2-cm2 culture wells at a concentration of 5 × 104 cells/ml. After a recovery period, cells were cultured under basal conditions or with 10-5 M forskolin alone or with 5 × 10-4 M aminoglutethimide for 24 h. When the LD50 of isocaproaldehyde was assayed, cells were exposed to increasing concentrations of isocaproaldehyde for 4 h. After treatments, cells were resuspended, and their viability was immediately estimated by 0.2% (w/v) trypan blue exclusion.

Statistics-- Results are given as means ± S.D. Statistical significance of the differences between treatment groups was determined by Student's t test.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Kinetic Properties of Recombinant MVDP-- To compare the enzymatic activities and substrate specificity of MVDP with those of mAR, both cDNAs were expressed in bacteria to obtain recombinant proteins. The kinetic constants of both proteins, determined for various substrates, are summarized in Table I. Similar to native AR purified from tissues, recombinant mAR has the ability to reduce aldo sugars, glyceraldehyde being the best substrate among them. Except for relatively lower Km values with glucose, values for recombinant mAR were in accordance with those reported for AR isolated from other species (20-23). By comparison with other compounds, isocaproaldehyde, methylglyoxal, and 4-hydroxynonenal were the best substrates. MVDP showed kinetic properties distinct from those of mAR. As shown in Table I, common substrates for AKR, including aldo sugars, were poor substrates for recombinant MVDP. For all compounds studied, the kcat values were always lower than those measured for mAR (Table I), even tested under various pH conditions (data not shown). Aldose reductases are able to use NADPH and also NADH, but with less efficiency (24-26). Other AKRs such as aldehyde or carbonyl reductases display a strict NADPH-dependent activity (27, 28). To determine the MVDP requirements for its cofactor, we also determined the kinetic constants for MVDP with NADH as a cofactor. When NADH was used instead of NADPH, the kcat values were 2-5-fold higher than those measured using NADPH, indicating that MVDP has a strong preference for NADH. Even though this enzyme shows a strong affinity for 4-hydroxynonenal, on the basis of comparison of the catalytic efficiencies (kcat), isocaproaldehyde seems to be the preferred substrate catalyzed by MVDP. Table II lists the effects of various compounds known as inhibitors of AR. Recombinant MVDP was not inhibited by Sorbinil and p-chloromercuribenzoate and was moderately diminished by Imirestat and Tolrestat, differing in this respect from recombinant mAR.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Kinetic constants for recombinant mAR and MVDP
The activity was assayed with 0.1 mM NADPH or 0.15 mM NADH as cofactor in 100 mM phosphate buffer (pH 6.6). The kcat values were calculated using molecular masses of 39.5 and 42 kDa for recombinant mAR and MVDP, respectively. Each value is the mean of at least six distinct experiments.

                              
View this table:
[in this window]
[in a new window]
 
Table II
Effect of inhibitors on recombinant mAR and MVDP
Aliquots of the inhibitor solution at the final concentrations indicated were added to the reaction mixture containing 100 mM phosphate buffer (pH 6.6), the enzymes, and isocaproaldehyde as substrate.

MVDP Reduces Isocaproaldehyde in Adrenocortical Cells-- Isocaproaldehyde, the best substrate identified for MVDP, is a product of the side-chain cleavage of cholesterol, the first step of steroid biosynthesis. On the basis of Western blot analysis, both MVDP and AR were detected in adrenal glands. By comparison with known amounts of recombinant proteins, the concentrations of MVDP and AR were found to be very similar, ~1% of total soluble proteins (Fig. 1). It has been shown that in murine adrenocortical cells, MVDP expression is up-regulated by forskolin (9). If isocaproaldehyde is reduced by MVDP in adrenocortical cells, it would be predicted that isocaproaldehyde reductase (ICR) activity should be enhanced by the addition of forskolin. However, since AR has been described as a major reductase for isocaproaldehyde in adrenal glands (18), we have developed a test to discriminate between AR and MVDP ICR activities. As shown in Fig. 2, treatment of Y1 cells for 24 h with 10-5 M forskolin strongly increased MVDP expression, whereas a 24-h exposure of the cells to hypertonic medium had no effect on MVDP levels. Conversely, AR levels were not affected by forskolin and were enhanced after exposure to hypertonic medium. As shown in Table III, no variation in NADPH-linked ICR activity was observed in cells stimulated by forskolin or exposed to hypertonic medium. When we used NADH instead of NADPH, a strong activity was measured in unstimulated cells. No stimulating effect was observed in cells exposed to hypertonic medium; however, when cells were exposed to forskolin treatment, NADH-linked ICR activity was strongly enhanced (~5-fold), and this effect was not abolished by the presence of Sorbinil and correlated with forskolin-induced MVDP expression. Similar experiments showed that NADH-linked 4-hydroxynonenal reductase activity was higher than NADPH-linked 4-hydroxynonenal reductase activity, but was not increased after forskolin exposure (Table III). Using the same experimental procedures, NADH-linked ICR activity in adult murine adrenal cytosolic extracts was estimated to ~150 µmol/min/mg of protein, and NADPH-linked ICR activity was determined to ~25 µmol/min/mg of protein extract.


View larger version (61K):
[in this window]
[in a new window]
 
Fig. 1.   MVDP and mAR levels in adrenal glands. Equivalent amounts of recombinant MVDP (A) or mAR (B) and 10 µg of total soluble adrenal proteins were subjected to SDS-PAGE and Western blot analysis using either an anti-MVDP monoclonal antibody or an anti-AR polyclonal antiserum.


View larger version (60K):
[in this window]
[in a new window]
 
Fig. 2.   Effect of forskolin and hyperosmotic stress on MVDP and mAR protein levels in adrenocortical Y1 cells. Cell cultures were untreated or treated with either forskolin- or hypertonic NaCl-supplemented medium for 24 h. Cell extracts were prepared, and 20 µg of cytosolic soluble proteins were subjected to SDS-PAGE and Western blotting using either an anti-AR polyclonal antiserum (A) or an anti-MVDP monoclonal antibody (B).

                              
View this table:
[in this window]
[in a new window]
 
Table III
ICR and 4-hydroxynonenal reductase activities in the murine adrenocortical Y1 cell line
The activities were assayed on Y1 cell cytosolic fractions with 0.12 mM NADPH or 0.216 mM NADH as cofactor in 100 mM phosphate buffer (pH 6.6). Values are the mean of four independent experiments.

MVDP Antisense cDNA Abolishes NADH-linked ICR Activity in Adrenocortical Cells-- Besides MVDP, the AKR1B subgroup contains proteins such as FR-1 (13) and human small intestine reductase (16), which are expressed in adrenal glands. To better understand the role of MVDP in adrenal glands, Y1 cells were stably transfected with the pCR3 vector containing MVDP antisense cDNA to prevent MVDP expression or with the empty vector as a control. Nine positive clones stably transfected with the pCR3 vector containing antisense cDNA and 12 clones transfected with the empty vector were selected after Southern blot analysis (data not shown). As expected, high levels of MVDP (Fig. 3) and strong NADH-linked ICR activity (Table IV) were observed after forskolin treatment in Y1 cells transfected with the empty vector (EV2 and EV4 cells). In contrast, MVDP and its mRNA were undetectable in Y1 cells transfected with MVDP antisense cDNA (AS19 cells) cultured either under basal conditions or with forskolin (Fig. 3, A and B). As MVDP and mAR display high homology in their nucleotide sequences, the presence of intact mAR protein levels was checked in these clones. As shown in Fig. 3A, mAR levels were not altered by MVDP antisense mRNA. In Y1 cells, in which antisense RNA completely abolishes MVDP expression (AS19 cells), no NADH-linked ICR was detected, indicating that ICR activity in adrenal glands is due mainly to MVDP (Table IV). Because basal NADH-linked ICR activity was totally blocked in AS19 cells, the presence of MVDP in EV4 cells cultured under basal conditions was checked to account for its involvement in NADH-linked ICR activity. Immunodetection using a highly titrated rabbit anti-MVDP antiserum demonstrated the presence of MVDP in EV4 cells cultured under basal conditions, whereas no MVDP expression was detected in AS19 cells cultured in the presence of forskolin (Fig. 3C).


View larger version (50K):
[in this window]
[in a new window]
 
Fig. 3.   Effect of MVDP antisense RNA on MVDP and mAR expression in neomycin-resistant Y1 cellular clones. Cellular clones stably transfected with pCR3-AS encoding MVDP antisense RNA (AS19) or with pCR3-EV (empty vector; EV2 and EV4) were treated with either forskolin (A and B) or NaCl (A). A, 20 µg of cytosolic proteins were subjected to SDS-PAGE and Western blotting as described in the legends to Figs. 1 and 2. B, RNA was isolated, and equivalent amounts of each sample (25 µg) were analyzed by Northern blot hybridization using 32P-labeled MVDP or beta -actin cDNA probes. C, 200 µg of cytosolic proteins from AS19 or EV4 cells cultured with or without 10-5 M forskolin, respectively, were subjected to NEpHGE (NEpHGE) and Western blotting using a highly titrated anti-MVDP polyclonal antiserum. Arrows indicate the position of the MVDP corresponding migration spot. The two other spots correspond to cross-reacting proteins unrelated to MVDP.

                              
View this table:
[in this window]
[in a new window]
 
Table IV
NADH- and NADPH-linked ICR activities in Y1 clones expressing or not MVDP antisense RNA
The activities were assayed on cytosolic fractions of Y1 cells stably transfected with an empty vector (EV) or MVDP antisense RNA-expressing vector (AS). Values are the mean of at least three independent experiments.

Forskolin and Isocaproaldehyde Toxicity Measurement-- Because forskolin is a potent activator of steroidogenesis in Y1 cells and therefore a potent activator of isocaproaldehyde production, we measured the viability of AS19 cells lacking MVDP ICR activity when treated with forskolin alone or with aminoglutethimide, an inhibitor of the first step of steroid synthesis.

The viability of MVDP-nonexpressing AS19 cells was significantly reduced after a 24-h forskolin exposure compared with EV4 cells (Fig. 4), and this effect was totally blocked when aminoglutethimide was simultaneously added to the medium, suggesting that forskolin is not toxic by itself, but works rather by stimulating the endogenous production of isocaproaldehyde through the enhancement of P450scc activity.


View larger version (48K):
[in this window]
[in a new window]
 
Fig. 4.   Effect of aminoglutethimide on forskolin-induced cell toxicity. Subconfluent EV4 or AS19 cells were treated with forskolin- and aminoglutethimide-supplemented medium for 24 h. After treatments, cell viability was estimated by trypan blue exclusion. Values are means ± S.D. of at least 12 experiments. *, significantly different from control (p < 0. 01).

LD50 was determined in EV4 and AS19 cells by adding increasing amounts of exogenous isocaproaldehyde (Fig. 5). Under our experimental conditions, LD50 was significantly decreased from 4.9 to 3 mM in cells lacking MVDP, demonstrating that MVDP ICR activity is important for detoxifying isocaproaldehyde.


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 5.   LD50 of isocaproaldehyde. Subconfluent EV4 and AS19 cells were treated with increasing isocaproaldehyde concentrations for 4 h. After treatments, cell viability was estimated as described in the legend to Fig. 4. Values are means ± S.D. of at least 12 experiments. *, significantly different from values obtained for EV4 cells exposed to the same isocaproaldehyde concentration (p < 0. 01).

Isocaproaldehyde Reductase Activity in H295R Cell Line-- As MVDP was also previously described to be expressed under forskolin control in the human adrenocortical H295R cell line (9), ICR activity was therefore investigated under the same experimental conditions described for Y1 cells (Table V). In H295R cells, as observed in Y1 cells, NADH-linked ICR activity was higher than NADPH-linked activity and was also enhanced by forskolin treatment, suggesting that in human adrenocortical cells, MVDP ICR activity is also required for detoxifying isocaproaldehyde.

                              
View this table:
[in this window]
[in a new window]
 
Table V
Isocaproaldehyde reductase activity in the human H295R cell line
The activities were assayed on cytosolic fractions with 0.12 mM NADPH or 0.216 mM NADH as cofactor in 100 mM phosphate buffer (pH 6.6). Values are the mean of three independent experiments.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Here we demonstrate that recombinant MVDP was active when tested with a variety of common substrates for AR. However, MVDP displayed kinetic properties distinct from those of classical AR. 1) MVDP has a strong preference for NADH; and 2) its enzymatic activity was highly insensitive to most AR inhibitors tested. Based on amino acid sequence identities, MVDP is more homologous to FR-1 (13), CHO reductase (14), ALR1 (15), and human small intestine reductase (16) than to AR (11). The kinetic properties determined for some of these enzymes indicate that they have different enzymatic activities over a range of substrates. This observation contrasts with the apparent conservation of the amino acid residues known to be involved in AR enzymatic activities. The key amino acids proposed to be involved in hydrogen transfer in AR (Tyr48, Asp43, Lys77, and Hist110) (23, 29, 30) and the 18 residues reported to interact with NADPH (Thr19, Trp20, Lys21, Asp43, Ser159, Asn160, Glu183, Tyr209, Ser210, Leu212, Ser214, Lys262, Ser263, Val264, Thr265, Arg268, Glu271, and Asn272) (31) are conserved within the five sequences, except a Glu at position 21 in CHO reductase. It has been shown that deletion of the last 13 amino acid residues at the C-terminal end of AR decreased catalytic effectiveness, suggesting that this region is crucial to proper orientation of substrates in the active pocket site (32). The C-terminal domains were more divergent among mAR, FR-1, CHO reductase, ALR1, human small intestine reductase, and MVDP, suggesting that these enzymes exhibit different substrate specificities in relation to their tissue distribution.

Whereas AR is present in many tested tissues, expression of MVDP, FR-1, CHO reductase, ALR1, and human small intestine reductase is restricted to a limited number of tissues. Some of these proteins have been shown to be induced by different factors, including hyperosmotic stress or an excess of galactose (AR) (3, 33), growth factors (FR-1) (13), chemical factors (CHO reductase) (14), or hormonal factors (MVDP) (8, 9). At present, it is not known whether ALR1 and human small intestine reductase, the human homologs, are also inducible. Then, the differences observed in kinetic properties, pattern of expression, and mechanisms of induction indicate that all these related proteins are probably involved in different physiological functions. The first step of steroidogenesis is the removal of the cholesterol side chain, resulting in the formation of pregnenolone and isocaproaldehyde (4-methylpentanal), which is metabolized to isocaproic acid and isocapryl alcohol (34). 4-Hydroxynonenal is a reactive aldehyde formed via peroxidative damage to polyunsaturated fatty acids in membrane phospholipids (35). On the basis of the catalytic efficiencies obtained with various substrates, isocaproaldehyde and 4-hydroxynonenal seem to be the preferred substrates catalyzed by recombinant MVDP. Since MVDP and mAR were expressed in similar amounts in adrenal glands, both enzymes may be responsible for the reduction of isocaproaldehyde and 4-hydroxynonenal generated by cellular metabolism. However, several lines of evidence suggest that MVDP, rather than AR, is a major reductase for isocaproaldehyde in murine adrenocortical cells. First, NADH-linked ICR activity (ascribed to MVDP) was higher than NADPH-linked ICR activity (attributed to AR). Second, NADH-linked ICR activity was not inhibited by specific AR inhibitors. Third, NADH-linked ICR activity was strongly enhanced by forskolin, which stimulates MVDP expression, but not by hyperosmotic stress inducing AR overexpression. Fourth, in Y1 cells stably transfected with MVDP antisense cDNA, NADH-linked ICR activity induced by forskolin was completely abolished. Our results differ from those of Matsuura et al. (18), who have shown that in human, monkey, dog, and rabbit adrenal glands, AR is a major reductase for isocaproaldehyde; but both NADH- and NADPH-linked ICR activities measured in the experiments of Matsuura et al. (18) are lower than those from our assay in cytosolic extracts. Some of the possible reasons for these dissimilar results include differences concerning species and experimental procedures. ICR activity has been previously measured in frozen adrenal extracts; in this study, we used fresh extracts of intact adrenal glands and fresh extracts of adrenocortical Y1 cells. Strikingly, in vitro kcat/Km values suggest that mAR/NADPH at equal concentration as is found in adrenal glands should be the main isocaproaldehyde reductase. Ex vivo experiments in Y1 cells contrast with this observation, suggesting that when produced in vitro from a bacterial expression system, MVDP is in a less effective state than when produced endogenously. In agreement with the observations of Grimshaw et al. (36) that activated or oxidized forms of human placenta aldose reductase result in an increase in Km, a net decrease in kcat/Km for DL-glyceraldehyde, and an insensitivity to Sorbinil inhibition, one possibility could be that in vitro produced MVDP exists in an oxidized form. Similarly, in Y1 cells lacking MVDP, NADH-linked 4-hydroxynonenal reductase activity is strongly reduced (data not shown). The results suggest that one function for MVDP, rather than mAR, in adrenocortical cells may be detoxification for protection against endogenous harmful aldehydes, including isocaproaldehyde and 4-hydroxynonenal. The biosynthesis of steroids is acutely and chronically stimulated by trophic hormones through the intermediary of cAMP (37). Interestingly, chronic effects of trophic hormones result from increased transcription of the genes that encode the steroidogenic enzymes (37) as well as MVDP (9), thereby maintaining optimal capacity for both steroid production and reduction of isocaproaldehyde. Immunodetection of MVDP in Leydig cell cultures2 suggests that MVDP plays this role in other steroidogenic cells.

    ACKNOWLEDGEMENTS

We thank Dr. D. A. Carper for the gift of the rabbit anti-rat aldose reductase antiserum. We are especially grateful to Dr. Veschambre for preparing isocaproaldehyde. We thank Drs. Jean-François Biellmann, Alain Van Dorsselaer, Alberto Podjarny, Patrick Barth, Hélène Rogniaux, and Benoit Viollet for helpful discussions and advice. We thank Dr. Laurent Morel for critical reading of the text. We thank Alain Halère and Jean-Paul Saru for technical assistance.

    FOOTNOTES

* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ To whom correspondence and reprint requests should be addressed. Tel.: 4-73-40-77-59; Fax: 4-73-40-70-42; E-mail: martinez@cicsun. univ-bpclermont.fr.

2 A.-M. Lefrançois-Martinez, C. Tournaire, A. Martinez, M. Berger, S. Daoudal, D. Tritsch, G. Veyssière, and C. Jean, unpublished data.

    ABBREVIATIONS

The abbreviations used are: AKRs, aldoketoreductases; AR, aldose reductase; mAR, murine aldose reductase; MVDP, mouse vas deferens protein; PAGE, polyacrylamide gel electrophoresis; ICR, isocaproaldehyde reductase; CHO, Chinese hamster ovary.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Bohren, K. M., Bullock, B., Wermuth, B., and Gabbay, K. H. (1989) J. Biol. Chem. 264, 9547-9551[Abstract/Free Full Text]
2. Gabbay, K. H. (1975) Annu. Rev. Med. 26, 521-536[CrossRef][Medline] [Order article via Infotrieve]
3. Bagnasco, S., Balaban, R., Fales, H., Yang, Y. M., and Burg, M. (1986) J. Biol. Chem. 261, 5872-5877[Abstract/Free Full Text]
4. Warren, J. C., Murdock, G. L., Ma, Y., Goodman, S. R., and Zimmer, W. E. (1993) Biochemistry 32, 1401-1406[CrossRef][Medline] [Order article via Infotrieve]
5. Grimshaw, C. E. (1992) Biochemistry 31, 10139-10145[CrossRef][Medline] [Order article via Infotrieve]
6. Taragnat, C., Berger, M., and Jean, C. (1988) J. Reprod. Fert. 83, 835-842[Abstract]
7. Lau, E., Cao, D., Lin, C., Chung, S. K., and Chung, S. S. (1995) Biochem. J. 312, 609-615
8. Martinez, A., Pailhoux, E., Berger, M., and Jean, C. (1990) Mol. Cell. Endocrinol. 72, 201-211[CrossRef][Medline] [Order article via Infotrieve]
9. Aigueperse, C., Martinez, A., Lefrançois-Martinez, A.-M., Veyssière, G., and Jean, C. (1998) J. Endocrinol. 160, 147-154
10. Pailhoux, E., Martinez, A., Veyssière, G., and Jean, C. (1990) J. Biol. Chem. 265, 19932-19936[Abstract/Free Full Text]
11. Daoudal, S., Berger, M., Pailhoux, E., Tournaire, C., Veyssière, G., and Jean, C. (1995) Life Sci. Adv. (Steroid Biochem.) 14, 45-58
12. Pailhoux, E., Veyssière, G., Fabre, S., Tournaire, C., and Jean, C. (1992) J. Steroid Biochem. Mol. Biol. 42, 561-568[CrossRef][Medline] [Order article via Infotrieve]
13. Donohue, P. J., Alberts, G. F., Hampton, B., and Winkles, J. A. (1994) J. Biol. Chem. 269, 8604-8609[Abstract/Free Full Text]
14. Hyndman, D. J., Takenoshita, R., Vera, N. L., Pang, S. C., and Flynn, T. G. (1997) J. Biol. Chem. 272, 13286-13291[Abstract/Free Full Text]
15. Cao, D., Fan, S. T., and Chung, S. S. M. (1998) J. Biol. Chem. 273, 11429-11435[Abstract/Free Full Text]
16. Hyndman, D. J., and Flynn, T. G. (1998) Biochim. Biophys. Acta 1399, 198-202[Medline] [Order article via Infotrieve]
17. Jez, J. M., Flynn, T. G., and Penning, T. M. (1997) Biochem. Pharmacol. 54, 639-647[CrossRef][Medline] [Order article via Infotrieve]
18. Matsuura, K., Deyashiki, Y., Bunai, Y., Ohya, I., and Hara, A. (1996) Arch. Biochem. Biophys. 328, 265-271[CrossRef][Medline] [Order article via Infotrieve]
19. Yasumura, Y., Buonassisi, V., and Sato, G. (1966) Cancer Res. 26, 529-535[Medline] [Order article via Infotrieve]
20. Iwata, N., Inazu, N., and Satoh, T. (1990) Arch. Biochem. Biophys. 282, 70-77[CrossRef][Medline] [Order article via Infotrieve]
21. Nishimura, C., Yamaoka, T., Mizutami, M., Yamashita, K., Akera, T., and Tanimoto, T. (1991) Biochim. Biophys. Acta 1078, 171-178[Medline] [Order article via Infotrieve]
22. Bohren, K. M., Page, J. L., Shankar, R., Henry, S. P., and Gabbay, K. H. (1991) J. Biol. Chem. 266, 24031-24037[Abstract/Free Full Text]
23. Carper, D. A., Hohman, T. C., and Old, S. E. (1995) Biochim. Biophys. Acta 1246, 67-73[CrossRef][Medline] [Order article via Infotrieve]
24. Boghosian, R. A., and McGuiness, E. T. (1979) Biochim. Biophys. Acta 567, 278-286[Medline] [Order article via Infotrieve]
25. Hadler, A. B., and Crabbe, M. J. C. (1984) Biochem. J. 219, 33-39[Medline] [Order article via Infotrieve]
26. Wermuth, B., Bürgisser, H., Bohren, K., and Von Wartburg, J. P. (1982) Eur. J. Biochem. 127, 279-284[Medline] [Order article via Infotrieve]
27. Turner, A. J., and Tipton, K. F. (1972) Biochem. J. 130, 765-772[Medline] [Order article via Infotrieve]
28. Wermuth, B., Münch, J. D. B., and Von Wartburg, J. P. (1977) J. Biol. Chem. 252, 3821-3828[Abstract/Free Full Text]
29. Tarle, I., Borhani, D. W., Wilson, D. K., Quiocho, F. A., and Petrash, J. M. (1993) J. Biol. Chem. 268, 25687-25693[Abstract/Free Full Text]
30. Bohren, K. M., Grimshaw, C. E., Lay, C. J., Harrisson, D. J., Ringe, D., Petsko, G. A., and Gabbay, K. H. (1994) Biochemistry 33, 2021-2032[CrossRef][Medline] [Order article via Infotrieve]
31. Wilson, D. K., Bohren, K. M., Gabbay, K. H., and Quiocho, F. A. (1992) Science 257, 81-84[Abstract/Free Full Text]
32. Petrash, J. M., Harter, T. M., Devine, C. S., Olins, P. O., Bhatnagar, A., Lui, S., and Srivastava, S. K. (1992) J. Biol. Chem. 267, 24833-24840[Abstract/Free Full Text]
33. Bekhor, I., Shi, S., and Unakar, N. J. (1990) Mol. Cell. Biochem. 95, 55-60[Medline] [Order article via Infotrieve]
34. Hall, P. F. (1970) in in The Testis (Johnson, A. D. , Gomes, W. R. , and Vandemark, N. L., eds) , pp. 1-72, Academic Press, New York
35. Esterbauer, H., Schaur, R. J., and Zollner, H. (1991) Free Radical Biol. Med. 11, 81-128[CrossRef][Medline] [Order article via Infotrieve]
36. Grimshaw, C. E, Bohren, K. M., Lai, C. J., and Gabbay, K. H. (1995) Biochemistry 34, 14366-14373[CrossRef][Medline] [Order article via Infotrieve]
37. Simpson, E. R., and Waterman, E. R. (1988) Annu. Rev. Physiol. 50, 427-440[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.



This article has been cited by other articles:


Home page
ReproductionHome page
C Baumann, B Davies, M Peters, U Kaufmann-Reiche, M Lessl, and F Theuring
AKR1B7 (mouse vas deferens protein) is dispensable for mouse development and reproductive success
Reproduction, July 1, 2007; 134(1): 97 - 109.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
J. Tirard, J. Gout, A. M. Lefrancois-Martinez, A. Martinez, M. Begeot, and D. Naville
A Novel Inhibitory Protein in Adipose Tissue, the Aldo-Keto Reductase AKR1B7: Its Role in Adipogenesis
Endocrinology, May 1, 2007; 148(5): 1996 - 2005.
[Abstract] [Full Text] [PDF]


Home page
J EndocrinolHome page
M.-C. Battista, C. Roberge, M. Otis, and N. Gallo-Payet
Seladin-1 expression in rat adrenal gland: effect of adrenocorticotropic hormone treatment
J. Endocrinol., January 1, 2007; 192(1): 53 - 66.
[Abstract] [Full Text] [PDF]


Home page
Toxicol PatholHome page
W. O. Ward, D. A. Delker, S. D. Hester, S.-F. Thai, D. C. Wolf, J. W. Allen, and S. Nesnow
Transcriptional Profiles in Liver from Mice Treated with Hepatotumorigenic and Nonhepatotumorigenic Triazole Conazole Fungicides: Propiconazole, Triadimefon, and Myclobutanil
Toxicol Pathol, December 1, 2006; 34(7): 863 - 878.
[Abstract] [PDF]


Home page
EndocrinologyHome page
B. Ragazzon, A.-M. Lefrancois-Martinez, P. Val, I. Sahut-Barnola, C. Tournaire, C. Chambon, J.-L. Gachancard-Bouya, R.-J. Begue, G. Veyssiere, and A. Martinez
Adrenocorticotropin-Dependent Changes in SF-1/DAX-1 Ratio Influence Steroidogenic Genes Expression in a Novel Model of Glucocorticoid-Producing Adrenocortical Cell Lines Derived from Targeted Tumorigenesis
Endocrinology, April 1, 2006; 147(4): 1805 - 1818.
[Abstract] [Full Text] [PDF]


Home page
Mol Hum ReprodHome page
Y. Azuma, T. Nishinaka, S. Ushijima, J. Soh, M. Katsuyama, H.-P. Lu, M. Kawata, C. Yabe-Nishimura, and T. Miki
Characterization of htAKR, a novel gene product in the aldo-keto reductase family specifically expressed in human testis
Mol. Hum. Reprod., July 1, 2004; 10(7): 527 - 533.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A.-M. Lefrancois-Martinez, J. Bertherat, P. Val, C. Tournaire, N. Gallo-Payet, D. Hyndman, G. Veyssiere, X. Bertagna, C. Jean, and A. Martinez
Decreased Expression of Cyclic Adenosine Monophosphate-Regulated Aldose Reductase (AKR1B1) Is Associated with Malignancy in Human Sporadic Adrenocortical Tumors
J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 3010 - 3019.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
D. H. Volle, J. J. Repa, A. Mazur, C. L. Cummins, P. Val, J. Henry-Berger, F. Caira, G. Veyssiere, D. J. Mangelsdorf, and J.-M. A. Lobaccaro
Regulation of the Aldo-Keto Reductase Gene akr1b7 by the Nuclear Oxysterol Receptor LXR{alpha} (Liver X Receptor-{alpha}) in the Mouse Intestine: Putative Role of LXRs in Lipid Detoxification Processes
Mol. Endocrinol., April 1, 2004; 18(4): 888 - 898.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
P. Val, C. Aigueperse, B. Ragazzon, G. Veyssiere, A.-M. Lefrancois-Martinez, and A. Martinez
Adrenocorticotropin/3',5'-Cyclic AMP-Mediated Transcription of the Scavenger akr1-b7 Gene in Adrenocortical Cells Is Dependent on Three Functionally Distinct Steroidogenic Factor-1-Responsive Elements
Endocrinology, February 1, 2004; 145(2): 508 - 518.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
A. Martinez, P. Val, I. Sahut-Barnola, C. Aigueperse, G. Veyssiere, and A.-M. Lefrancois-Martinez
Steroidogenic Factor-1 Controls the Aldose Reductase akr1b7 Gene Promoter in Transgenic Mice through an Atypical Binding Site
Endocrinology, May 1, 2003; 144(5): 2111 - 2120.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
P. Val, A. Martinez, I. Sahut-Barnola, C. Jean, G. Veyssiere, and A.-M. Lefrancois-Martinez
A 77-Base Pair LINE-Like Sequence Elicits Androgen-Dependent mvdp/akr1-b7 Expression in Mouse Vas Deferens, But Is Dispensable for Adrenal Expression in Rats
Endocrinology, September 1, 2002; 143(9): 3435 - 3448.
[Abstract] [Full Text] [PDF]


Home page
J AndrolHome page
T. Kobayashi, T. Kaneko, Y. Iuchi, S. Matsuki, M. Takahashi, I. Sasagawa, T. Nakada, and J. Fujii
Localization and Physiological Implication of Aldose Reductase and Sorbitol Dehydrogenase in Reproductive Tracts and Spermatozoa of Male Rats
J Androl, September 1, 2002; 23(5): 674 - 683.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
D. Sarkar, T. Imai, F. Kambe, A. Shibata, S. Ohmori, A. Siddiq, S. Hayasaka, H. Funahashi, and H. Seo
The Human Homolog of Diminuto/Dwarf1 Gene (hDiminuto): A Novel ACTH-Responsive Gene Overexpressed in Benign Cortisol-Producing Adrenocortical Adenomas
J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5130 - 5137.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
C. Aigueperse, P. Val, C. Pacot, C. Darne, E. Lalli, P. Sassone-Corsi, G. Veyssiere, C. Jean, and A. Martinez
SF-1 (Steroidogenic Factor-1), C/EBP{beta} (CCAAT/Enhancer Binding Protein), and Ubiquitous Transcription Factors NF1 (Nuclear Factor 1) and Sp1 (Selective Promoter Factor 1) Are Required for Regulation of the Mouse Aldose Reductase-Like Gene (AKR1B7) Expression in Adrenocortical Cells
Mol. Endocrinol., January 1, 2001; 15(1): 93 - 111.
[Abstract] [Full Text]


Home page
EndocrinologyHome page
E. Brockstedt, M. Peters-Kottig, V. Badock, C. Hegele-Hartung, and M. Lessl
Luteinizing Hormone Induces Mouse Vas Deferens Protein Expression in the Murine Ovary
Endocrinology, July 1, 2000; 141(7): 2574 - 2581.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
B. Crosas, E. Cederlund, D. Torres, H. Jornvall, J. Farres, and X. Pares
A Vertebrate Aldo-keto Reductase Active with Retinoids and Ethanol
J. Biol. Chem., May 25, 2001; 276(22): 19132 - 19140.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow